348 related articles for article (PubMed ID: 22707408)
1. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.
Oishi N; Kumar MR; Roessler S; Ji J; Forgues M; Budhu A; Zhao X; Andersen JB; Ye QH; Jia HL; Qin LX; Yamashita T; Woo HG; Kim YJ; Kaneko S; Tang ZY; Thorgeirsson SS; Wang XW
Hepatology; 2012 Nov; 56(5):1792-803. PubMed ID: 22707408
[TBL] [Abstract][Full Text] [Related]
2. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
Gurzu S; Szodorai R; Jung I; Banias L
J Cancer Res Clin Oncol; 2024 May; 150(5):270. PubMed ID: 38780656
[TBL] [Abstract][Full Text] [Related]
3. VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
Xu H; Lin X; Li Z; He X; Li Y; Qiu L; Lu L; Liu B; Zhan M; He K
J Gastroenterol; 2023 Sep; 58(9):925-944. PubMed ID: 37391589
[TBL] [Abstract][Full Text] [Related]
4. MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition.
Gao C; Li J; Zeng F; Wang L; Chen K; Chen D; Hong J; Qu C
Carcinogenesis; 2023 Jun; 44(4):279-290. PubMed ID: 37185675
[TBL] [Abstract][Full Text] [Related]
5. A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma.
Plieskatt J; Rinaldi G; Feng Y; Peng J; Easley S; Jia X; Potriquet J; Pairojkul C; Bhudhisawasdi V; Sripa B; Brindley PJ; Bethony J; Mulvenna J
BMC Cancer; 2015 Apr; 15():309. PubMed ID: 25903557
[TBL] [Abstract][Full Text] [Related]
6. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway.
Zhang H; Yang J; Song Q; Ding X; Sun F; Yang L
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):199-209. PubMed ID: 38298057
[TBL] [Abstract][Full Text] [Related]
7. Liensinine inhibits progression of intrahepatic cholangiocarcinoma by regulating TGF-β1 /P-smad3 signaling through HIF-1a.
Zhu X; Bao W; Xie X; Chen B; Li R; Zhao J; Wu L; Yu Z; Li S; Zhu Q; Chen G; Li J
Mol Carcinog; 2024 Apr; 63(4):772-784. PubMed ID: 38289159
[TBL] [Abstract][Full Text] [Related]
8. Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma.
Jeon Y; Kwon SM; Rhee H; Yoo JE; Chung T; Woo HG; Park YN
Hepatology; 2023 Jan; 77(1):92-108. PubMed ID: 35124821
[TBL] [Abstract][Full Text] [Related]
9. Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis.
Shen Z; Cai J; Tao L; Zheng J; Ye Z; Liu Y; Pan H; Wang Y; Xu J; Liang X
Cancer Gene Ther; 2023 Dec; 30(12):1663-1678. PubMed ID: 37828105
[TBL] [Abstract][Full Text] [Related]
10. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract][Full Text] [Related]
11. Single-cell and spatial architecture of primary liver cancer.
Zhou PY; Zhou C; Gan W; Tang Z; Sun BY; Huang JL; Liu G; Liu WR; Tian MX; Jiang XF; Wang H; Tao CY; Fang Y; Qu WF; Huang R; Zhu GQ; Huang C; Fu XT; Ding ZB; Gao Q; Zhou J; Shi YH; Yi Y; Fan J; Qiu SJ
Commun Biol; 2023 Nov; 6(1):1181. PubMed ID: 37985711
[TBL] [Abstract][Full Text] [Related]
12. Tumor-matrix interaction induces phenotypic switching in liver cancer cells.
Yuan RH; Hsu CL; Jhuang YL; Liu YR; Hsieh TH; Jeng YM
Hepatol Int; 2022 Jun; 16(3):562-576. PubMed ID: 35525880
[TBL] [Abstract][Full Text] [Related]
13. DAGLβ is the principal synthesizing enzyme of 2-AG and promotes aggressive phenotype of intrahepatic cholangiocarcinoma via AP-1/DAGLβ/miR4516 feedforward circuitry.
Ma M; Zeng G; Tan B; Zhao G; Su Q; Zhang W; Song Y; Liang J; Xu B; Wang Z; Chen J; Hou M; Yang C; Yun J; Huang Y; Lin Y; Chen D; Han Y; DeMorrow S; Liang L; Lai J; Huang L
Am J Physiol Gastrointest Liver Physiol; 2023 Sep; 325(3):G213-G229. PubMed ID: 37366545
[TBL] [Abstract][Full Text] [Related]
14. A Novel Trojan Horse Nanotherapy Strategy Targeting the cPKM-STMN1/TGFB1 Axis for Effective Treatment of Intrahepatic Cholangiocarcinoma.
Chen ZW; Kang FP; Xie CK; Liao CY; Li G; Wu YD; Lin HY; Zhu SC; Hu JF; Lin CF; Huang Y; Tian YF; Huang L; Wang ZW; Chen S
Adv Sci (Weinh); 2023 Nov; 10(32):e2303814. PubMed ID: 37789644
[TBL] [Abstract][Full Text] [Related]
15. CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m
Zhou S; Yang K; Chen S; Lian G; Huang Y; Yao H; Zhao Y; Huang K; Yin D; Lin H; Li Y
J Transl Med; 2023 Jan; 21(1):43. PubMed ID: 36691046
[TBL] [Abstract][Full Text] [Related]
16. Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma.
Kitagawa A; Osawa T; Noda M; Kobayashi Y; Aki S; Nakano Y; Saito T; Shimizu D; Komatsu H; Sugaya M; Takahashi J; Kosai K; Takao S; Motomura Y; Sato K; Hu Q; Fujii A; Wakiyama H; Tobo T; Uchida H; Sugimachi K; Shibata K; Utsunomiya T; Kobayashi S; Ishii H; Hasegawa T; Masuda T; Matsui Y; Niida A; Soga T; Suzuki Y; Miyano S; Aburatani H; Doki Y; Eguchi H; Mori M; Nakayama KI; Shimamura T; Shibata T; Mimori K
Br J Cancer; 2023 Jun; 128(12):2206-2217. PubMed ID: 37076565
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib.
Yu Y; Liu Q; Li W; Qu Y; Zhang Y; Liu T
Oncologist; 2020 Dec; 25(12):1005-1008. PubMed ID: 32897609
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Clinical Use of Molecular Profiling of Intrahepatic Cholangiocarcinoma in a Comprehensive Multidisciplinary Clinic.
Purchla J; Ghabi EM; Burns WR; Lafaro KJ; Burkhart RA; Cameron JL; Yarchoan M; Shubert CR; Baretti M; He J
J Am Coll Surg; 2024 Apr; 238(4):532-540. PubMed ID: 38189646
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.
Sia D; Tovar V; Moeini A; Llovet JM
Oncogene; 2013 Oct; 32(41):4861-70. PubMed ID: 23318457
[TBL] [Abstract][Full Text] [Related]
20. Asbestos and Intrahepatic Cholangiocarcinoma.
Brandi G; Tavolari S
Cells; 2020 Feb; 9(2):. PubMed ID: 32059499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
